A detailed history of Victory Capital Management Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Victory Capital Management Inc holds 204,205 shares of NBIX stock, worth $25.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
204,205
Previous 137,543 48.47%
Holding current value
$25.6 Million
Previous $18.9 Million 24.16%
% of portfolio
0.02%
Previous 0.02%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$114.58 - $153.15 $7.64 Million - $10.2 Million
66,662 Added 48.47%
204,205 $23.5 Million
Q2 2024

Aug 05, 2024

BUY
$130.86 - $143.19 $219,321 - $239,986
1,676 Added 1.23%
137,543 $18.9 Million
Q1 2024

May 03, 2024

BUY
$130.4 - $143.74 $2.43 Million - $2.68 Million
18,646 Added 15.91%
135,867 $18.7 Million
Q4 2023

Feb 05, 2024

BUY
$106.07 - $132.76 $5.03 Million - $6.29 Million
47,389 Added 67.86%
117,221 $15.4 Million
Q3 2023

Nov 06, 2023

BUY
$94.02 - $117.1 $43,531 - $54,217
463 Added 0.67%
69,832 $7.86 Million
Q2 2023

Jul 27, 2023

SELL
$89.53 - $104.87 $986,978 - $1.16 Million
-11,024 Reduced 13.71%
69,369 $6.54 Million
Q1 2023

May 02, 2023

SELL
$94.11 - $123.02 $3.1 Million - $4.05 Million
-32,945 Reduced 29.07%
80,393 $8.14 Million
Q4 2022

Feb 10, 2023

BUY
$106.72 - $127.06 $1.37 Million - $1.63 Million
12,797 Added 12.73%
113,338 $13.5 Million
Q4 2022

Feb 09, 2023

BUY
$106.72 - $127.06 $286,116 - $340,647
2,681 Added 2.74%
100,541 $12 Million
Q3 2022

Nov 02, 2022

BUY
$92.03 - $107.81 $1.15 Million - $1.35 Million
12,535 Added 14.69%
97,860 $10.4 Million
Q2 2022

Aug 01, 2022

SELL
$75.79 - $100.07 $52,674 - $69,548
-695 Reduced 0.81%
85,325 $8.32 Million
Q1 2022

May 04, 2022

BUY
$72.45 - $94.81 $5.03 Million - $6.58 Million
69,412 Added 417.94%
86,020 $7.74 Million
Q4 2021

Feb 07, 2022

SELL
$79.65 - $106.22 $337,556 - $450,160
-4,238 Reduced 20.33%
16,608 $1.42 Million
Q3 2021

Nov 02, 2021

SELL
$86.18 - $99.03 $1.58 Million - $1.82 Million
-18,334 Reduced 46.79%
20,846 $2 Million
Q2 2021

Aug 03, 2021

SELL
$89.43 - $102.27 $177,518 - $203,005
-1,985 Reduced 4.82%
39,180 $3.81 Million
Q1 2021

May 04, 2021

SELL
$87.57 - $119.4 $30 Million - $40.9 Million
-342,211 Reduced 89.26%
41,165 $4 Million
Q4 2020

Feb 01, 2021

SELL
$86.91 - $108.33 $27.7 Million - $34.5 Million
-318,735 Reduced 45.4%
383,376 $36.7 Million
Q3 2020

Nov 09, 2020

BUY
$96.16 - $135.15 $5.7 Million - $8.01 Million
59,279 Added 9.22%
702,111 $67.5 Million
Q2 2020

Aug 07, 2020

BUY
$85.09 - $130.36 $5.92 Million - $9.08 Million
69,631 Added 12.15%
642,832 $78.4 Million
Q1 2020

May 04, 2020

SELL
$75.11 - $113.76 $4.99 Million - $7.57 Million
-66,500 Reduced 10.4%
573,201 $49.6 Million
Q4 2019

Feb 06, 2020

BUY
$86.8 - $118.57 $890,134 - $1.22 Million
10,255 Added 1.63%
639,701 $68.8 Million
Q4 2019

Feb 04, 2020

BUY
$86.8 - $118.57 $16.4 Million - $22.5 Million
189,450 Added 43.06%
629,446 $63 Million
Q3 2019

Nov 12, 2019

BUY
$83.82 - $101.5 $14.5 Million - $17.5 Million
172,526 Added 64.5%
439,996 $39.6 Million
Q2 2019

Aug 15, 2019

SELL
$72.24 - $91.27 $19.4 Million - $24.5 Million
-268,630 Reduced 50.11%
267,470 $22.6 Million
Q1 2019

May 03, 2019

SELL
$69.31 - $91.53 $1.18 Million - $1.56 Million
-17,085 Reduced 3.09%
536,100 $47.2 Million
Q4 2018

Feb 05, 2019

SELL
$68.32 - $124.36 $3.55 Million - $6.46 Million
-51,950 Reduced 8.58%
553,185 $39.5 Million
Q3 2018

Nov 01, 2018

BUY
$98.88 - $125.85 $22.6 Million - $28.7 Million
228,163 Added 60.53%
605,135 $74.4 Million
Q2 2018

Aug 02, 2018

SELL
$75.3 - $105.99 $14.5 Million - $20.4 Million
-192,628 Reduced 33.82%
376,972 $37 Million
Q1 2018

May 04, 2018

BUY
$75.88 - $92.43 $43.2 Million - $52.6 Million
568,940 Added 86203.03%
569,600 $47.2 Million
Q2 2017

Aug 07, 2017

BUY
N/A
660
660 $30,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.